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Abstract
Background: The HIV-1 protease is initially synthesized as part of the Gag-Pol polyprotein in the infected cell.
Protease autoprocessing, by which the protease domain embedded in the precursor catalyzes essential cleavage
reactions, leads to liberation of the free mature protease at the late stage of the replication cycle. To examine
autoprocessing reactions in transfected mammalian cells, we previously described an assay using a fusion precursor
consisting of the mature protease (PR) along with its upstream transframe region (p6*) sandwiched between GST
and a small peptide epitope.
Results: In this report, we studied two autoprocessing cleavage reactions, one between p6* and PR (the proximal
site) and the other in the N-terminal region of p6* (the distal site) catalyzed by the embedded protease, using our
cell-based assay. A fusion precursor carrying the NL4-3 derived protease cleaved both sites, whereas a precursor
with a pseudo wild type protease preferentially autoprocessed the proximal site. Mutagenesis analysis
demonstrated that several residues outside the active site (Q7, L33, N37, L63, C67 and H69) contributed to the
differential substrate specificity. Furthermore, the cleavage reaction at the proximal site mediated by the
embedded protease in precursors carrying different protease sequences or C-terminal fusion peptides displayed
varied sensitivity to inhibition by darunavir, a catalytic site inhibitor. On the other hand, polypeptides such as a
GCN4 motif, GFP, or hsp70 fused to the N-terminus of p6* had a minimal effect on darunavir inhibition of either
cleavage reaction.
Conclusions: Taken together, our data suggest that several non-active site residues and the C-terminal flanking
peptides regulate embedded protease activity through modulation of the catalytic site conformation. The cell-
based assay provides a sensitive tool to study protease autoprocessing reactions in mammalian cells.
Background
HIV-1 protease (PR) is one of three virus-encoded
enzymes essential for virus propagation and infectivity.
The catalytic site of protease has been mapped to resi-
due D25. Alteration of D25 to A, Y, H, or N completely
abolishes enzymatic activity [1-4]. In the HIV-1 infected
cell, the protease is initially synthesized as part of the
Gag-Pol polyprotein precursor, within which the HIV-1
protease is flanked at the N-terminus by a transframe
region named TFR or p6*, and at the C-terminus by the
reverse transcriptase (RT) [2,5,6]. The regulated cleavage
reactions, in which the Gag-Pol precursor is both the
enzyme and substrate, lead to liberation of the free
mature HIV-1 PR. This process is generally referred to
as protease autoprocessing.
The released mature HIV-1 PR forms stable dimers
and recognizes at least 10 different cleavage sites in the
Gag and Gag-Pol polyproteins. Accurate and precise
protease processing of these sites is absolutely required
for the production of infectious progeny virions [7-13].
Therefore, the mature HIV-1 protease has been the pri-
mary target of anti-HIV drug development. In fact,
unprecedented efforts from academic and industrial
laboratories have made the mature HIV-1 protease one
of the most-studied enzymes, as documented by numer-
ous reports and reviews published over last 20 years
[2,14-20]. These efforts have led to development of ten
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FDA-approved HIV-1 protease inhibitors for clinical
applications. These inhibitors, however, all belong to the
same mechanistic class–they are designed to bind to the
catalytic site of the mature protease. Such single-mode
inhibition is insufficient to completely suppress HIV-1
replication as drug resistant strains often emerge in
patients under treatment. Therefore, novel therapeutic
inhibitors with different mechanisms of action are
urgently needed for the treatment of HIV-1 infection.
In distinct contrast to the extensive studies on the
mature protease, the molecular and cellular mechanisms
of HIV-1 protease autoprocessing are largely undefined.
It is known that the protease domain embedded in the
precursors is essential and sufficient to mediate autopro-
cessing because various precursors containing an active
PR domain are able to release the mature protease when
expressed in vitro [3,21], in E. coli [1,5,22-24], or in
mammalian cells [8,25]. Of the two cleavage reactions
that liberate the mature protease, the C-terminal clea-
vage reaction appears to be nonessential for virus repli-
cation. A mutation that blocks this cleavage site leads to
production of PR-RT fusion enzymes, but the resulting
viruses remain viable and infectious [26]. A transient
intermediate consisting of the mature PR and a portion
of the native C-terminal flanking sequence (the first 19
residues of RT) demonstrated proteolytic kinetics similar
to the mature protease [27]. In addition, fusion of fluor-
escent proteins such as CFP and YFP to the C-terminus
had no effect on protease dimerization and proteolytic
activity [28]. In contrast, the N-terminal cleavage reac-
tion is critical for liberation of the fully active mature
protease. A p6*-PR fusion was unable to process most
of the cleavage sites in the Gag polyprotein, leading to
the production of noninfectious virions [29,30]. Removal
of the p6* peptide was required for mature protease
activity [23]. These studies have established the p6*-PR
as a miniprecursor for autoprocessing characterization
[5,23,24,31,32].
Structural information on the embedded protease is
currently unavailable in spite of more than 500 reported
structures for the mature protease. Therefore, the
mechanism by which the embedded protease mediates
the autoprocessing cleavage reactions remains obscure.
To facilitate examination of the cleavage reactions
involved in protease autoprocessing, we previously engi-
neered a fusion precursor consisting of a miniprecursor
(p6*-PR) sandwiched between GST and a small peptide
epitope (Figure 1A). GST was chosen as the N-terminal
p6*-PR tag to stimulate precursor dimerization, which is
believed to be important for the formation of a catalytic
site based on the mature protease structure. The disso-
ciation constant for GST dimerization is in the low nM
range [33-35], and the GST C-termini are in close
proximity in the crystallized GST dimer (PDB 3KMN).
Because a protease antibody with high sensitivity is not
available, a C-terminal peptide epitope was included to
facilitate detection of the precursor substrate and pro-
cessing products. The resulting fusion precursor effec-
tively autoprocessed in E. coli and in transfected
mammalian cells, and faithfully reproduced autoproces-
sing phenotypes observed in other systems [24,25]. This
design provided an easy assay to study protease autopro-
cessing reactions inside cells, which differs from conven-
tional studies in which proteolysis kinetics is
characterized using purified mature proteases and syn-
thetic peptide substrates in a test tube.
In this report, we examined two cleavage reactions
involved in protease autoprocessing using protease inhi-
bitors as a structural probe to gain insights into the cat-
alytic site conformation of the protease under different
contexts. Our data demonstrated that different protease
constructs displayed varying sensitivities to inhibition by
the currently available protease inhibitors, suggesting
the existence of more than one catalytic site conforma-
tion. Interestingly, several surface residues far from the
PR catalytic site, and residues adjacent to the PR C-ter-
minus, also regulated the activity of the embedded pro-
tease involved in the autoprocessing cleavage reactions.
Our data highlights a different catalytic mechanism driv-
ing liberation of the mature protease and provides a
glimpse of the embedded protease as it functions during
autoprocessing.
Results and Discussion
Different protease precursors demonstrate different
cleavage preferences
A previously constructed fusion precursor contains two
native cleavage sites, one between p6* and PR (the prox-
imal (P) cleavage site) and the other at the N-terminal
region of p6* (the distal (D) cleavage site) (Figure 1A).
We tested two precursors with slightly different protease
sequences [25]. One was derived from the NL4-3 strain,
denoted as PRNL hereafter; the other was a pseudo wild
type protease, PRpse, which was engineered to reduce
protease self degradation (Q7K, L33I, and L63I) and
protein aggregation mediated by thiol oxidation (C67A
and C95A) for structural analysis of the mature protease
in vitro [5,23,31]. When expressed in transfected mam-
malian cells, the mature PRpse is also self degraded [25].
There are a total of six residues that are different
between PRNL and PRpse; all others are identical in these
precursors (Figure 1A). Interestingly, the PRpse precursor
predominantly autoprocessed the P site whereas the
PRNL precursor autoprocessed both sites with a slight
preference for D site cleavage (Figure 1C). Because the
amino acid sequences at both cleavage sites are the
same, we speculated the difference in substrate specifi-
city is due to the difference in protease.
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To identify which residues are attributed to the differ-
ent substrate preference, we constructed a panel of
PRpse precursors containing individual or combinatorial
amino acid substitutions reflecting those present in
PRNL (Figure 1A). Autoprocessing analysis of the
resulting precursors demonstrated that a single Q7
mutation changed the cleavage preference from PRpse-
like to PRNL-like, whereas a single C95 mutation did
not. Also, we previously observed a PRNL-like autopro-
cessing phenomenon when single residue H69 was
Figure 1 Autoprocessing of fusion precursors with different protease sequences. (A) Schematic diagram of the fusion precursors. The p6*
sequence is derived from the NL4-3 strain, which contains two native cleavage sites, the distal (D) and proximal (P) sites, as indicated. (B) Space
fill representation of two mature protease structures with the relevant surface amino acids highlighted in different colors. Top, an NL4-3 protease
with residue S37 (the NL4-3 protease structure with N37 residue is not available); bottom, a pseudo wild type protease. (C) Autoprocessing of
different precursors in transfected HEK293T cells. Post-nuclear cell lysates were prepared from cells transfected with plasmids encoding the
indicated fusion precursors and subjected to western blot analysis. The blot was simultaneously probed using polyclonal rabbit anti-GST (upper)
and mouse anti-HA (lower) primary antibodies, followed by IR700 goat anti-rabbit and IR800 goat anti-mouse secondary antibodies for
concurrent visualization with an Odyssey infrared dual laser scanning unit. At right, the products released by the cleavage reaction at the D site
are connected by a dotted line and those released by P site cleavage by a solid line.
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changed to Q, K, E or D in the PRpse backbone [25].
Single amino acid alterations at residues 33, 37, 63, or
67 did not change the cleavage preference, but the
L33N37 and L63C67 double mutants displayed PRNL-
like autoprocessing patterns. According to the crystal
structure of the mature protease dimer, these residues
are mostly surface exposed and far away from the active
site (Figure 1B). These data suggest that multiple pro-
tease residues influence substrate preference of the
embedded protease. Residues such as Q7 and H69
altered cleavage preferences by single amino acid muta-
tion; others like L33N37 and L63C67 changed cleavage
preferences by double mutation. These residue(s) or
residue pair(s) are spread out on the mature protease
surface, and they each seem to be sufficient to alter
cleavage preferences. Our results are consistent with
previous reports demonstrating that alterations in many
non-active site residues are associated with evolution of
drug resistant proteases causing formation of a catalytic
site insensitive to a protease inhibitor yet active in pro-
teolysis function [36-39].
It is very intriguing that different proteases display dif-
ferent preferences to the D and P cleavage sites. Since
the cleavage sequences are identical in these fusion con-
structs, we suggest that different proteases have different
catalytic sites that determine different substrate prefer-
ences. One could argue that different substrate accessi-
bility might also be attributed to the observed
difference. Although it is possible that the P site accessi-
bility is altered by the adjacent PR, it is difficult to
explain how the PRpse could render the D site nonclea-
vable as it is separated from the protease by a flexible
peptide (p6*). Therefore, we are inclined to suggest that
different embedded proteases display different substrate
preferences.
The released proteases demonstrate different sensitivities
to darunavir inhibition of self degradation
We next utilized darunavir, the most potent HIV-1 pro-
tease inhibitor, as a structural probe to examine the cat-
alytic site conformation of various proteases. Darunavir
binds to the catalytic site of the mature protease with
low nanomolar affinity [40,41]. A previous study demon-
strated that the most stable conformation of darunavir is
very similar to that observed in the X-ray structure of
darunavir in complex with the protease dimer [42].
Therefore, effective inhibition is expected if the catalytic
site conformation readily accommodates darunavir; less
suppression of proteolytic activity would be anticipated
if the catalytic site is different from that reported in the
mature protease structure.
The wild type p6*-PRNL fusion precursor carries two
native cleavage sites, D and P, respectively. To examine
whether the cleavage reactions at these two sites
interfere with each other, we engineered two fusion pre-
cursors to examine the individual reaction. The P site
was mutated in the MG precursor, and the D site was
deleted in the M1 precursor [25] (Figure 2A). Autopro-
cessing of the resulting precursors was essentially the
same as observed with the wild type fusion precursor
(Figure 2B-D), suggesting minimal interference between
these two cleavage reactions in transfected cells. This
also suggests that the secondary cleavage reactions
mediated by the released proteases are minimal probably
due to rapid diffusion and self degradation (below) in
the cytoplasm of transfected cells.
We next examined effects of darunavir on the released
proteases. In the absence of darunavir, the two PR-con-
taining products, PRNL-HA and p6*-PRNL-HA, were not
detectable likely due to rapid self degradation [43], while
the GST-containing fragments were readily detectable
(Figure 2B-D, left). In the presence of darunavir (8-300
nM), protease self degradation was inhibited such that
the PRNL-HA and p6*-PRNL-HA fragments became
detectable (Figure 2B-D, middle). Further increase in
darunavir concentration reduced the amount of PR-con-
taining products that were released. We interpreted this
as a result of two relatively independent reactions. One
reaction is self degradation of released PRNL-HA or p6*-
PRNL-HA, the other is the cleavage reaction mediated by
the embedded protease that liberate the autoprocessing
products. Quantification of band intensities demon-
strated the darunavir concentration where peak detec-
tion of the released protease was observed (Figure 2,
right). At this concentration, the cleavage reaction
mediated by the embedded protease was minimally sup-
pressed as indicated by minimal accumulation of the full
length precursor and effective production of GST-con-
taining fragments. Accordingly, we were able to deter-
mine the IC50 to suppress self degradation (denoted by
the asterisks).
The released PRpse-HA was less sensitive than PRNL-
HA to darunavir inhibition of self degradation (Figure
2D&E), suggesting a difference in catalytic site confor-
mation between these two mature proteases. Consistent
with our observation, a slight difference in enzyme
kinetics was reported between the mature PRpse and
PRNL proteases when tested in vitro [23]. In addition,
the p6*-PRNL-HA displayed a self degradation IC50 (~60
nM) approximately 6-fold higher than that for PRNL-HA
(~10 nM), suggesting that they are not enzymatically
identical. This is consistent with a previous report
demonstrating that p6*-PR is incapable of processing
many of the cleavage sites in the Gag polyprotein nor-
mally processed by the mature protease [30]. Taken
together, our data indicate that the catalytic site confor-
mation is modulated by different amino acid sequences
in the mature protease (PRpse vs. PRNL) and also by the
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p6* peptide fused to the N-terminus of the mature pro-
tease (PRNL vs. p6*-PRNL).
It should be noted that the self degradation IC50
determined in our system is very similar to the IC50
identified for the mature protease activity in HIV-1
infected cells. Darunavir has an IC50 of ~5 nM to inhibit
the production of p24 [40,41], whereas self degradation
IC50 for PR
NL-HA was ~10 nM. The slight difference
might be attributed to varied protein concentrations. At
least two factors might be attributed to this slight differ-
ence. One factor is different readouts; the ~5 nM
reflects the darunavir concentration required to achieve
50% inhibition of p24 production whereas the ~10 nM
represents the concentration required to suppress the
Figure 2 Different fusion precursors respond differentially to darunavir inhibition. All fusion precursors were derived from the GST-p6*-PR-
HA construct. Differences in the p6* region are highlighted on the top (A). The p6*-PRNL (B) contains the wild type NL4-3 protease sequence
with two native cleavage sites. The P site was mutated in the MG-PRNL construct (C); the D site was deleted in the M1- PRNL precursor (D) as
previously described [25]. The p6*-PRpse precursor (E) is similar to the p6*-PRNL except that it contains the pseudo wild type protease sequence.
The p6*-PRH69D (F) precursor carries H69D point mutation in the p6*-PRNL backbone. Precursor autoprocessing in transfected HEK293T cells was
examined in the presence of increasing concentrations of darunavir. Post-nuclear cell lysates were prepared at 30 h post transfection and
subjected to western blot analysis. Each blot was simultaneous probed using polyclonal rabbit anti-GST (left) and mouse anti-HA (middle)
primary antibodies, respectively, for dual visualization through two separate infrared channels. Open triangles indicate the apparent IC50 (left) for
the cleavage reaction mediated by the embedded protease. Asterisks denote the IC50 for self degradation of the released PR-HA and p6*-PR-HA
(middle). The band intensity of each PR-containing fragment was quantified, normalized to the highest pixel value (1000), and plotted against
darunavir concentrations (right). Thick lines with solid symbols represent PR-HA produced by P site cleavage reaction; thin lines with open
symbols represent p6*-PR-HA produced by D site cleavage reaction.
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mature protease from self degradation by 50%. The
other factor is varied protein concentrations. Subse-
quently, more darunavir is required to suppress PR-HA
self degradation in our cell-based assay. Nevertheless,
our result is in agreement with the established darunavir
IC50, further validating the utility of our assay for pro-
tease activity and autoprocessing analyses.
The embedded protease is less sensitive than the mature
protease to darunavir inhibition
With our assay system, the P and D site cleavage reac-
tions are primarily catalyzed by the embedded protease
as the released mature protease either is quickly self
degraded or rapidly diffuses away in the absence of a
Gag lattice as in a progeny virion. Darunavir binding to
the embedded protease is expected to inhibit the clea-
vage reaction especially if the catalytic site conformation
of the embedded protease is similar to that of the
mature protease. According to the amount of the
released GST protein, we estimated the apparent half
maximal inhibition concentration (IC50) of the D site
reaction to be ~7500 nM darunavir, as indicated by
open triangles (Figure 2B and 2C, left). This is ~125-
fold higher than the self degradation IC50 of the released
p6*-PRNL-HA (~60 nM). The same trend was observed
for the P site cleavage reaction, which had an apparent
IC50 of ~1500 nM, i.e., ~150-fold higher than the self
degradation IC50 of PR
NL-HA (~10 nM). Additionally,
the cleavage reaction IC50 of the embedded p6*-PR
pse
was ~7500 nM, whereas the self degradation IC50 for
the released PRpse was ~40 nM (Figure 2E). It is intuitive
to assume that the embedded protease and the free
mature protease fold into similar structures with similar
catalytic site conformations. However, our data demon-
strated that the embedded protease is at least 100-fold
less sensitive to darunavir inhibition than the corre-
sponding released protease. This observation is consis-
tent with a previous study reporting that an in vitro
translated Gag-Pol precursor displayed significantly low
sensitivity to ritonavir inhibition compared to the
mature protease [21]. One might argue that this could
be attributed to differences in dimerization ability of the
embedded proteases as it is a prerequisite for the forma-
tion of a catalytic site. If it is the case, one should expect
increased sensitivity to darunavir inhibition as the p6*
peptide and darunavir treatment are mostly known to
decrease protease dimerization [3,23,28,44,45], thus less
functional catalytic sites are formed. In contrast, we
observed low sensitivity, i.e., active autoprocessing at
high darunavir concentrations. Therefore, we interpreted
that the low sensitivity to darunavir inhibition is due to
the fact that the embedded protease has a catalytic site
conformation different from that found in their corre-
sponding mature protease.
Autoprocessing analysis of the PRNL H69D precursor
further supported the idea that various catalytic site con-
formations exist (Figure 2F). The H69D mutation
abolishes protease autoprocessing in the context of pro-
viral constructs [46]. In our cell-based assay, the H69D
fusion precursor autoprocessed both the D and P sites
with low efficiency, as indicated by the presence of the
full-length precursor in the lysate. Interestingly, the
released PR-containing products were clearly detectable in
the absence of darunavir, suggesting the released proteases
were not degraded. Furthermore, darunavir treatment did
not increase the amount of the released proteases, arguing
for the existence of a catalytic site conformation that is
resistant to darunavir inhibition. Similarly, autoprocessing
reactions mediated by the embedded H69D PR were not
suppressed by darunavir, suggesting that its catalytic site is
not recognized by darunavir.
We also tested autoprocessing of a few fusion precur-
sors against indinavir, another well characterized pro-
tease inhibitor, and observed very similar results (Figure
3). The indinavir autoprocessing profiles were reminis-
cent to the darunavir ones, suggesting that our reported
phenotypes herein are consistent with these two pro-
tease inhibitors. We conclude that the embedded and
mature proteases with the same sequence display differ-
ent catalytic site conformations, and that several pro-
tease residues modulate the catalytic site conformation
in both the embedded and mature proteases.
An indinavir resistant precursor is not resistant to
darunavir inhibition
To further test the idea that different proteases have dif-
ferent catalytic site conformations, we constructed a
fusion precursor carrying V77I and V82D. This double
mutation was identified in a patient resistant to indina-
vir treatment [47]. The self degradation IC50 was ~150
nM and ~300 nM for the wild type and resistant mature
protease, respectively (Figure 4). The mutant mature
protease is thus ~two-fold less sensitive than the wild
type protease to indinavir inhibition of self degradation,
confirming a small difference in catalytic site conforma-
tion attributed to indinavir resistance. Consistent with
our result, previous structural analysis revealed that the
three-dimensional structures of the wild type protease
or a multi-drug-resistant variant in complex with indi-
navir were only slightly different [48,49]. Interestingly,
this subtle difference was not detected by darunavir;
both wt and mutant mature proteases showed a self
degradation IC50 of ~20 nM darunavir (Figure 4D,
insert). Our data suggest that darunavir binds to the
protease variants with similar affinity and kinetics
despite the slight structural difference, providing evi-
dence that darunavir is a better choice for treating drug
experienced patients.
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The cleavage reaction mediated by the embedded
protease showed an apparent indinavir IC50 between
300 nM and 1500 nM for the wild type precursor (Fig-
ure 4B) and an apparent IC50 between 1500 nM and
7500 nM (Figure 4A) for the mutant precursor. There-
fore, the mutation rendered greater drug resistance
(~5-fold) to the cleavage reaction than to self degrada-
tion of the mature protease, suggesting that the muta-
tion also causes a change in the catalytic site
conformation of the embedded protease, which seems
to contribute more to indinavir resistance. Once again,
darunavir inhibited the cleavage reaction mediated by
the control or mutant precursor to a similar extent
(Figure 2D and 4C), confirming that darunavir is more
effective and able to inhibit activity of an indinavir
resistant protease. Collectively, our data illustrated that
our assay is sensitive enough to detect subtle differ-
ences in the catalytic site between an indinavir resis-
tant mutant (V77I/V82D) and its parental PRNL
precursor, and that flexibility of catalytic site confor-
mation is involved in regulation of both embedded and
mature protease activities.
Figure 3 Different fusion precursors respond differentially to indinavir inhibition. All fusion precursors were derived from the GST-p6*-PR-
HA construct. Differences in the PR region are listed on the top. Precursor autoprocessing in transfected HEK293T cells was examined in the
presence of increasing indinavir concentrations. Post-nuclear cell lysates were prepared at 30 h post transfection and subjected to western blot
analysis. Each sample was probed using mouse anti-Flag (top) or anti-HA (bottom) primary antibodies in parallel. Open triangles indicate the
apparent IC50 for the embedded protease. Asterisks denote self degradation IC50 of the released PR-HA and p6*-PR-HA. The products released by
the cleavage reaction at the D site are connected by a dotted line and those at the P site by a solid line.
Figure 4 An indinavir resistant precursor is not resistant to darunavir inhibition. An indinavir resistant mutation (V77I/V82D) was
introduced to the GST-M1-PRNL-HA backbone. Autoprocessing of the resulting construct with increasing concentrations of indinavir (A) or
Darunavir (C) was compared to that of the parental precursor in the presence of indinavir (B) and darunavir (Figure 2D). Each blot was
simultaneous probed and visualized through two infrared channels. The asterisks denote the self degradation IC50 of the released PR-HA; the
open triangles denote the apparent IC50 of the cleavage reaction. The amounts of the released PR-HA from the parental (open circle) and
mutant (solid square) precursor were quantified, normalized, and plotted against indinavir (D) or darunavir (D, inset) concentrations.
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C-terminal fusions moderately regulate the proximal site
cleavage reaction
To examine whether different amino acid sequences
fused to the C-terminus of PR influence protease autop-
rocessing, we engineered a panel of fusion precursors
carrying different C-terminal epitopes (Figure 5A). A
truncated version of M2 p6* (Figure 2A) was used to
allow focused examination of the P site cleavage reac-
tion. We also constructed GST-M2-PR, a precursor
lacking any C-terminal epitope, to serve as a reference
control. Self degradation IC50 of each the released pro-
teases was between 16-32 nM darunavir, suggesting that
small C-terminal peptide fusions have a minimal effect
on the catalytic site conformation of the mature pro-
tease such that they were inhibited by darunavir simi-
larly from self degradation. In contrast, different tags
exhibited different effects on darunavir inhibition of the
cleavage reaction catalyzed by the embedded protease.
With the tagless precursor, the cleavage reaction was
not suppressed even with 7500 nM darunavir. The
apparent IC50 was ~1500 nM for the Myc- and HA-
tagged precursors. The Flag and V5 peptides made the
precursor more sensitive to darunavir inhibition (appar-
ent IC50 ~300 nM) than the HA and Myc epitopes,
although there is no obvious correlation between the
lengths or charge properties of the tags with this
observed difference. Our data suggested that the
embedded protease activity was modulated by different
C-terminal tags, but self degradation of the mature pro-
tease after it was released from the precursor was not
significantly affected by these tags. One possible cause
for the increased sensitivity to darunavir could be that
the C-terminal tags increased difficulty in precursor
dimerization, and thus less active site were formed and
less darunavir were required to suppress their catalytic
activity. Alternatively, the C-terminal tag could directly
modulate the enzymatic activity of the embedded pro-
tease by influencing the catalytic site conformation. Bio-
physical and structural analyses of these proteases are
essential to definitely distinguish the possible causes.
To gain further insight into the effect of C-terminal
flanking sequences on protease autoprocessing, we
Figure 5 Autoprocessing of precursors with different C-terminal tags. All fusion precursors were derived from GST-M2-PRNL-Flag for specific
examination of P site cleavage reaction. (A) The sequences at the junction between the PR and the C-terminal tag of some constructs are listed.
(B) Autoprocessing of precursors carrying different small peptide epitopes or no tag were analyzed using a mouse epitope-specific antibody
(Flag, Myc, HA), polyclonal rabbit anti-V5, or anti-PR as underlined at left, and GST primary antibodies for dual visualization. Because the signal
detected by anti-PR antibody was weak, the boxed region was enhanced to show the mature protease (bottom). Autoprocessing of precursors
fused to a GCN4 motif (C) or to reverse transcriptase (RT) in which the native cleavage site between PR and RT remained cleavable (E) or was
mutated to uncleavable (D) were also compared. Asterisks indicate self degradation IC50 of the PR-containing product; open triangles indicate
the apparent IC50 of the cleavage reaction. The expected products from P site cleavage reaction are connected by a solid line.
Huang et al. Retrovirology 2011, 8:79
http://www.retrovirology.com/content/8/1/79
Page 8 of 12
constructed more fusion precursors containing longer
C-terminal fusions. The GCN4 dimerization motif
derived from a yeast transcription factor [50-52] was
directly fused to the C-terminus of the mature PR fol-
lowed by Flag (Figure 5A). We chose the GCN4 motif
to induce precursor dimerization from the C-terminus
of the protease. The released PR-GCN4-Flag displayed a
self degradation IC50 ~20 nM darunavir, whereas the
IC50 for the cleavage reaction was greater than 1500
nM. This was similar to the HA-tagged fusion precur-
sor. We also detected additional fragments likely pro-
duced as a result of cleavage reactions at alternative
sites at high darunavir concentrations, suggesting the
existence of a catalytic conformation(s) induced by daru-
navir binding that process amino acid sequences not
recognized at low darunavir concentrations. These data
further confirmed that the embedded protease is much
less sensitive to darunavir inhibition and its activity
could be influenced by different C-terminal peptides
that are adjacent to it.
In the Gag-Pol polyprotein precursor, the PR domain
is followed by reverse transcriptase (RT), and there are
reports suggesting a possible contribution of RT to reg-
ulation of protease activity [53,54]. We generated RT-
containing precursors with the native cleavage site
mutated (PR-RT) or kept unchanged (PR/RT) to exam-
ine their autoprocessing. The overall expression levels of
the resulting precursors were much lower than the
other precursors, likely because the reverse transcriptase
coding sequence is not optimized for high levels of
expression in transfected cells [55]. Nonetheless, self
degradation IC50 of the released PR-RT-Flag was at the
low nanomolar range (2-4 nM), and the cleavage reac-
tion mediated by the embedded protease displayed an
apparent IC50 of ~60 nM darunavir (Figure 5D). We
were unable to detect the RT-Flag released from the
precursor carrying the native cleavage site between PR
and RT (Figure 5E), while the cleavage reaction demon-
strated an IC50 of ~60 nM darunavir. The apparent high
sensitivity to darunavir inhibition could be due to the
low expression levels such that less darunavir were
required to suppress the cleavage reaction. Alternatively,
the catalytic site of the RT fusion precursors and the
released PR-RT enzyme fits better for darunavir binding.
Additional analyses using precursor constructs with
compatible levels of expression would be necessary to
further define the underlying cause of the decreased dar-
unavir requirement. We also observed a possible alter-
native cleavage reaction at a site within the reverse
transcriptase as indicated by a GST-containing fragment
with an apparent MW greater than GST-M2-PR,
whereas the other Flag-containing fragment was unde-
tectable. This cleavage reaction occurred when daruna-
vir concentrations were between 8 nM and 300 nM,
suggesting a different catalytic conformation formed in
this concentration range. This reaction was completely
suppressed at high concentrations of darunavir. Taken
together, these data suggest that different C-terminal
flanking sequences could influence the proteolytic activ-
ity of the embedded protease by modulating the catalytic
site conformation, revealing an additional dimension of
protease complexity arising from plasticity of the
embedded protease active site conformation.
N-terminal fusions do not affect precursor autoprocessing
To examine the role of N-terminal fusions on precursor
autoprocessing, we replaced the GST with a GCN4
motif, GFP or hsp70. Both the D and P cleavage sites
were included in these constructs and a Flag peptide
was in-frame fused to the motif/proteins to simplify
detection. All three fusion precursors were autopro-
cessed effectively in the absence of darunavir, as indi-
cated by the disappearance of the fusion precursor
(Figure 6). The released fragments GCN4-Flag and
GCN4-Flag-p6* were too small to detect by SDS-PAGE.
The released PR-HA and p6*-PR-HA showed self degra-
dation IC50s that were very similar to the corresponding
values observed for the fragments released from the
GST fusion precursors (Figure 2A). At high darunavir
concentrations, the GFP precursor released extra frag-
ments which is likely due to a cleavage reaction at an
alternative site. The cleavage reactions at the D or P
sites catalyzed by the embedded protease also displayed
similar response profiles to darunavir inhibition as the
GST fusion precursor (Figure 2A). This data suggested
that fusions at the N-terminus of p6* do not signifi-
cantly influence the catalytic site conformation of the
embedded protease, likely because they are separated
from the protease domain by a long and flexible peptide
(p6*).
Conclusions
In this study, we studied two proteolysis reactions
involved in HIV-1 protease autoprocessing in trans-
fected cells expressing engineered fusion precursors.
Protease inhibitors designed to specifically bind to the
catalytic site of the mature protease were used as struc-
tural probes to examine the catalytic site conformation.
Our analyses demonstrated that both the protease
sequence and the protease context (free mature vs
embedded with flanking peptides) affect the catalytic
site conformation, which in turn alter the response sen-
sitivity to inhibition by catalytic site inhibitors. Several
non-active site residues as well as residues flanking the
protease also contributed to modulation of catalytic site
conformation. Our results are consistent with extensive
structural studies that demonstrate multiple slightly dif-
ferent catalytic site conformations in mature protease as
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a molecular basis for the evolution of drug resistant
strains. The advantage of our assay is simplicity without
a compromise of sensitivity, allowing for broad applica-
tion in the examination of the protease autoprocessing
mechanism and/or in the identification and characteri-
zation of novel anti-HIV drugs. Our results also imply
that novel inhibitors targeting important surface resi-
dues may be developed as alternative therapeutic agents.
An encouraging report along this vein identified a novel
inhibitor from combinatorial libraries that suppresses
HIV-1 protease activity likely through binding to a
groove outside of the catalytic site [56]. Identification of
such inhibitors that interfere with protease activity via
modes of action different from the current protease
inhibitors will provide new promises for future develop-
ment of therapies to defeat the spread of HIV-1.
Methods
DNA mutagenesis
Construction of plasmids encoding GST-p6*-PRNL-HA,
GST-p6*-PRpse-HA, GST-p6*-PRpse D25N-HA, GST-
p6*-PRNLH69D-HA, GST-M1-PRNL-HA, and GST-M2-
PRNL-HA was previously described [25]. Additional
mutations described herein were introduced into the
indicated plasmids by standard PCR-mediated mutagen-
esis and cloning procedures. Mutations Q7, L33, N37,
L33N37, L63, C67, L63C67 and C95 were individually
introduced into the GST-P6*-PRpse-HA expression plas-
mid. The GST-p6*-MG-PRNL-HA construct was gener-
ated by mutating the amino acids at the P site (from
TVSFSF⇓PQIT to TVMG⇓PQIT) to block proteolytic
cleavage. The indinavir resistant mutation V77V82 was
cloned into the plasmid encoding GST-M1-PRNL-HA.
To generate fusion precursors with various C-terminal
sequences, the Flag tag coding sequence in GST-M2-
M2-PRNL-Flag was replaced by sequences encoding the
indicated epitopes, motif or proteins. Similarly, the GST
coding sequence in the GST-Flag-PRNL-HA expression
plasmid was replaced with GCN4, GFP, or Hsp70 [57]
encoding sequence for expression of fusion precursors
containing different N-terminal sequences. All the con-
structs were verified by sequencing analysis and detailed
plasmid information is available upon request.
Cell culture and transfection
HEK293T cells (ATCC, Manassas, VA) were maintained
in DMEM containing 10% fetal bovine serum and peni-
cillin/streptomycin (0.6% Penicillin G sodium salt, 1.0%
Streptomycin sulfate, 0.85% NaCl). Plasmid DNA was
transfected into HEK293T cells using calcium phosphate
as previously described [25,46]. Briefly, HEK293T cells
were seeded in 12-well plates the day before transfection
to achieve 50~60% confluence at the time of transfec-
tion. About 1 h prior to transfection, chloroquine was
added into each well to a final concentration of 25 μM.
A total of 0.5 μg plasmid DNA in 65.7 μl H2O was
mixed with 9.3 μl of 2 M CaCl2. Then 75 μl of 2xHBS
(50 mM Hepes, pH7.04~7.05, 10 mM KCl, 12 mM Dex-
trose, 280 mM NaCl, 1.5 mM Na2HPO4) was added to
the DNA-Ca mixture followed by gentle agitation. The
resulting mixture was directly added drop-wise to each
well. Protease inhibitors darunavir (NIH AIDS research
and reference program, Cat# 8145) and indinavir (NIH
AIDS research and reference program, Cat# 11447)
were dissolved in autoclaved H2O to generate 250 μM
darunavir and 10 mM indinavir stock solutions, respec-
tively; these were stored at -20°C. darunavir or indinavir
were then diluted and added to cells directly after trans-
fection at the indicated working concentration. After 7-8
h incubation at 37°C, 5% CO2, the transfection medium
Figure 6 Autoprocessing of precursors with different N-terminal tags. The GST portion in the GST-p6*-PR-HA construct (Figure 2A) was
replaced with a GCN motif (left), GFP (middle), or Hsp70 (right), respectively. The resulting precursors also contained a Flag peptide upstream of
the D site. Blots were probed using either mouse anti-Flag (upper) or mouse anti-HA (lower) primary antibodies. The dotted lines connect the
products expected from D site cleavage reaction and solid lines connect the products from P site cleavage reaction. The GCN4- containing
products were too small to detect by SDS-PAGE.
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was replaced with fresh chloroquine-free medium con-
taining the corresponding protease inhibitors. At 30 h
post-transfection, cells were washed once with PBS and
lysed with 100 μl lysis buffer A (Tris-HCl, pH8.0, 150
mM NaCl, 1% sodium deoxycholate, and 1% Triton X-
100, and protease inhibitor cocktail). Cell lysates were
clarified by brief centrifugation at 20800 × g for 2 min-
utes and stored at -20°C for further western blot
analysis.
Western blotting and quantification
Primary antibodies used in this study include polyclonal
rabbit anti-GST (a kind gift from Dr. Santiago DiPietro,
Colorado State University), anti-V5 (Rockland, Cat# 600-
401-378), anti-HIV1 protease (NIH AIDS research and
reference program, Cat# 4105); mouse monoclonal anti-
HA (Sigma, Cat# H9658), anti-flag (Sigma, Cat# F1804),
and anti-myc (purified from culture medium of hybri-
doma cells, ATCC, Cat# CRL-1729). Secondary antibo-
dies included IR700 goat anti-rabbit (Rockland, Cat#
611-130-122) and IR800 goat anti-mouse (Rockland,
Cat# 610-132-121). For protein detection, about 1/6 of
the cell lysate from one well of a 12 well plate was sub-
jected to SDS-PAGE followed by western blot analysis.
The blots were probed simultaneously or separately with
the corresponding primary and secondary antibodies, and
visualized with an Odyssey infrared dual laser scanning
unit (LI-COR Biotechnology, Lincoln, Nebraska). To
reduce background noise, the rabbit anti-HIV protease
antibody was first incubated with cell lysates from
untransfected 293T cells that had been resolved by SDS-
PAGE and transferred onto a PVDF membrane.
For quantification of protein intensity, Western blot
images captured by an Odyssey infrared dual laser scan-
ning unit were analyzed using TotalLab software (Non-
linear Dynamics Inc.). The total pixel volume of each
band was quantified and normalized; the highest value
was arbitrarily set at 1000.
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